November 10, 2026

The General Manager
Pakistan Stock Exchange Limited Stock
Exchange Building Stock Exchange Road
Karachi.

Subject: Corporate Briefing Session Liven Pharma Limited

Dear Sir,
In compliance with regulations 5.7.3 of Pakistan Stock Exchange Regulations, a Corporate Briefing Session (CBS) of Liven Pharma Limited, is scheduled to be held on November 18, 2026, Wednesday at 2:30 PM through Zoom. The session will provide shareholders, investors and analysts with an overview of the Company's financial performance for the year.

Zoom link is given below to attend CBS;
Join Zoom Meeting

Liven Pharma Limited is inviting you to a scheduled Zoom meeting.

Topic: Liven Pharma Limited Corporate Briefing Session 2026
Time: Nov 18, 2026 02:30 PM Islamabad, Karachi, Tashkent

Join Zoom Meeting
https://us05web.zoom.us/j/86909548847?pwd=8bwkkpWidviRJm0XifZCzzQSSv4ik7.1

Meeting chat link
https://us05web.zoom.us/launch/jc/86909548847

Meeting ID: 869 0954 8847
Passcode: 5BHstJ

You may please inform the TRE Certificate Holders of the Exchange accordingly.
Thaning you

Muhammad Saeed

Company Secretary

A l l S e t - G o o d T o G o

General Manager

Pakistan Stock Exchange - Karachi

Public Limited Company • PSX: LIVEN • DML No. 000881

49-Km, Multan Road, Lahore, Pakistan

NOVEMBER 2026 EXECUTIVE BRIEFING

Live – Invest – Grow

Corporate Briefing

Session - 2026

Live with Health

LIVEN PHARMA LIMITED

Public Limited Company • PSX: LIVEN • DML No. 000881

49-Km, Multan Road, Lahore, Pakistan

NOVEMBER 2026

EXECUTIVE BRIEFING

AGENDA

01 Company Profile & Corporate Information

02 Board of Directors & Leadership

03 Vision, Mission & Values

04 Core Business & Manufacturing

05 Journey & Product Portfolio

06 Certifications & Regulatory Licenses

07 Market Standing & Key Brands

08 Global Presence & Future Outlook

COMPANY PROFILE

Who We Are

Liven Pharma Limited is a public listed pharmaceutical company (PSX: LIVEN) engaged in the manufacturing and marketing of high-quality medicines across multiple therapeutic categories. Formerly Private Limited entity, the company completed its strategic transformation into a public listed company to grow as the most advance and completely integrated self sufficient Pharmaceutical company of Pakistan.

2018 – 2024 *	**000881**	**95,600 sq ft**
Established	DML Number	Facility Area
6 Sections	**120+**	**86.8%**
Dosage Forms	Registered Molecules	Shareholding (Sponsors)

AT A GLANCE

- Public Limited Company listed on Pakistan Stock Exchange
- State-of-the-art manufacturing facility at 49-Km Multan Road, Lahore
- cGMP compliant with full DRAP licensing
- ISO 9001, ISO 14001 & ISO 45001 certified
- Active export presence in multiple countries
- Strong focus on injectables, psychotropics & specialty formulations
- Shariah-compliant operations
- Experienced leadership with deep pharmaceutical sector roots

CORPORATE INFORMATION

Shareholding Structure

Category	Percentage
Sponsors	86.8%
Individuals	3.53%
Free Float	5.0%
Physical	4.67%

Key Corporate Facts

Legal Status
Public Limited Company under Companies Act, 2017

Listed On
Pakistan Stock Exchange (PSX: LIVEN)

Principal Activity
Manufacturing of Pharmaceuticals & Allied Products

Registered Office
49-Km, Multan Road, Lahore, Pakistan

DML
000881 (Formulation) – Issued 11 April 2018

cGMP Status
Compliant – Certificate valid 3 years from inspection

Shariah Status
Shariah Compliant Company

Contact
+92 (3) 111 0 LIVEN | info@liven-pharma.com

BOARD OF DIRECTORS & MANAGEMENT

Board of Directors

Mr. Atif Hussain	Chairman of the Board
Mr. Kaashif Hussain	Chief Executive Officer
Mr. Umar Mujeeb Shami	Non-Executive Director
Mr. Usman Mujeeb Shami	Non-Executive Director
Ms. Firdous Shakir	Director
Mr. Ahmad Shoaib Hashmi	Independent Director
Mr. Syed Raza Abbas	Independent Director

Key Management

Pir Muhammad Shah	Chief Financial Officer
Abdullah Shareef	Deputy CFO
M. Saeed	Company Secretary (ADV)
Nadeem Waraich	Business Unit Head
Dr. M. Ayaz	Plant Manager
Muhammad Umar	Quality Control Manager
Saraan Saeed	Admin Officer
Dr Marium	Business Development Manager

VISION, MISSION & VALUES

VISION

To make Liven one of the top pharmaceutical manufacturing companies in the Sub-Continent by 2030.

To make Pakistan independent in the manufacturing of Active Pharmaceutical Ingredients (APIs).

To establish the most advanced biological manufacturing unit in South East Asia.

To invest decisively in the future of healthcare.

MISSION

Be a hope for patients and medical practitioners.

Create a company that produces wonders in the field of medicine.

Build a Green Pakistan through CSR and by encouraging others to do the same.

Become a place of satisfaction for investors, sponsors and, most importantly, employees.

LIVEN is a promise — a hope, a life, and a driving force for quality of life.

CORE BUSINESS AREAS

Six Licensed Dosage Forms

Tablets

General – Mixing, Granulation, Compression, Coating, Blistering

Capsules

General – Mixing, Encapsulation, Polishing, Blistering

Oral Dry Powder Sachets

General – Mixing, Filling & Packaging

Liquid Injectable (Ampoule)

General – Mixing, Filling & Packaging

Liquid Injectable (Vial)

General – Mixing, Filling & Packaging

Liquid Injectable (Psychotropic)

Controlled / Psychotropic – Mixing, Filling & Packaging

MANUFACTURING FACILITY

95,600	32,600	120+	6
sq ft	sq ft		
Total Land Occupied	Manufacturing & Utilities	Registered Products	Dosage Form Sections

Recent Capability Investments

01

Automatic Blistering & Cartoning Line

Fully commissioned Chinese line improving packing quality and lifting overall capacity by 12–15%.

02

Automatic Injectable System

Complete automatic system for injectable manufacturing — 40–45% efficiency gain and reduced breakage/losses.

03

Rights Issue – PKR 200 Million

Fresh capital for working capital, CAPEX (Dry Powder Injectables), vehicles and DRAP licensing.

OUR JOURNEY

2018	Drug Manufacturing License (DML 000881) granted – 6 sections
2019	cGMP compliance achieved; commercial production begins
2022	Listing process initiated
2024	Listing completed – Liven Pharma Limited (PSX: LIVEN)
2025	Introduction of Automation and Capacity enhancement
2026	Successful Right issue, and

CERTIFICATIONS & REGULATORY LICENSES

Drug Manufacturing License

DML No. 000881

Formulation – 6 Sections
Issued: 11 April 2018
Renewed: 2023

cGMP Certificate

DRAP

Inspection: 27 Feb 2024
Valid 3 years
WHO-aligned format

ISO 9001:2015

Quality Management

Cert No. EC-12135L154-Q
Issue: Dec 2023
Scope: Pharma Manufacturing

ISO 14001:2015

Environmental Mgmt

Cert No. EC-12135L154-E
Issue: Dec 2023
PNAC Accredited

ISO 45001:2018

OH&S Management

Cert No. EC-12135L154-O
Issue: Dec 2023
Occupational Health & Safety

PRODUCT PORTFOLIO HIGHLIGHTS

Analgesics & NSAIDs

Ketorolac, Diclofenac, Tramadol, Nalbuphine, Paracetamol Infusion

Antibiotics

Azithromycin, Ciprofloxacin, Levofloxacin, Linezolid, Co-Amoxiclav

Proton Pump Inhibitors

Omeprazole, Esomeprazole, Pantoprazole

CNS / Psychotropics

Midazolam, Diazepam, Buprenorphine, Pregabalin, Escitalopram

Vitamins & Others

Colecalciferol (D3), Vitamin B Complex, Iron, Statins (Rosuvastatin, Atorvastatin)

Specialty / New

Letrozole, Tamsulosin, Fluconazole, Remdesivir (REM-D), Napolive (Na-free)

MARKET STANDING – SELECTED THERAPIES

Illustrative ranking in key molecules (IQVIA / market data references from company materials)

Olam

Strong presence

Major player in injectable NSAID segment

Paracetamol + Tramadol

Competitive

Significant volume in combination analgesic

Azithromycin

Growing

Active in oral antibiotic category

Colecalciferol (D3)

Notable

Injectable & oral vitamin D portfolio

Nalbuphine

Established

Psychotropic / analgesic injectable

Kotamor

Building

CNS / neuropathic pain segment

GLOBAL PRESENCE & EXPORTS

Current & Expanding Markets

Afghanistan	**DRC Congo**	**Kazakhstan**	**Senegal**
Uzbekistan	**Vietnam**	**Yemen**	**Others (Road to Export)**

Strategic Direction

Liven is actively expanding its export footprint with a focus on Central Asia, Southeast Asia and the Middle East. Recent MoU with China's TOFFLON Science & Technology Group supports technology collaboration, localization of selected processes, and the company's Vision 2030 to become an integrated pharmaceutical & biotechnology enterprise.

CAPITAL MARKET & GROWTH INITIATIVES

Rights Issue

PKR 200 Million

20M shares @ PKR 10

Paid-up Impact

~21.5%

of current paid-up capital

New Products

30+

via toll manufacturing

Focus Areas

Injectables

+ specialized formulations

Strategic Use of Proceeds & Pipeline

- Working capital strengthening for scale-up
- Procurement of vehicles & distribution assets
- Wider-scale marketing campaigns & HCP engagement
- Capital expenditure – Dry Powder Injectables division
- Regulatory licensing with DRAP
- Expansion of distribution network across Pakistan

FUTURE OUTLOOK – VISION 2030

API Manufacturing

Establish domestic Active Pharmaceutical Ingredient production capability to reduce import dependence.

Biologicals

Develop advanced biological manufacturing unit positioned among the most modern in South East Asia.

Medical Devices

Expand into testing kits and selected medical devices to broaden healthcare portfolio.

International Certifications

Pursue PICS and MHRA-level certifications to unlock high-value export markets.

Technology Partnership

Deepen collaboration with TOFFLON (China) for process technology and localization.

Digital & Sustainability

Invest in digitalization, green operations and CSR to build long-term resilience and brand equity.

THANK YOU

We look forward to building lasting partnerships in health.

Liven Pharma Limited

Beyond Reality

49-Km, Multan Road, Lahore, Pakistan
+92 (3) 111 0 LIVEN | info@liven-pharma.com
www.liven-pharma.com

PSX: LIVEN • ISO Compliant • cGMP Compliant